Glioblastoma Foundation

The research achievements of the Glioblastoma Foundation in 2022 involved continuing funding for leading edge research for targeted treatments for Glioblastoma, providing patient support resources for families and patients diagnosed with Glioblastoma, and raising awareness of this rare grade 4 brain cancer. During the 2022 year we continued to fund research for the combination drug therapy of lomustine and temozolomide for newly diagnosed Glioblastoma patients, funded research into patient and caregiver qualify of life after diagnosis research, and a targeted research study on Glioblastoma cancer cell metabolism processes and drugs to stop Glioblastoma cell growth. We also moved forward on our goal to manufacture lomustine at a reduced rate for patients by partnering with continuity pharma in the productive of lomustine active pharmaceutical ingredient. This project is currently underway to bring lomustine to patients at a lower cost. We also continued our patient programs to provide clinical trials matching to patients after a Glioblastoma diagnosis and continued to host our award-winning support group for patients and caregivers, called the Glioblastoma support circle.